Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

A groundbreaking study by the National Institutes of Health (NIH) is shifting the conversation around hormone therapy and ...

Young patients with advanced Hodgkin's lymphoma, a cancer of the lymphatic system, now have a better chance of having their ...

Associations between hormone therapy and young-onset breast cancer (diagnosed at younger than 55 years) vary, according to a study published online in the July issue of The Lancet Oncology.

Menopause causes a range of symptoms. Some supplements may help. Learn which menopause supplements can help ease symptoms.

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs ...

The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...

As early-onset cancers rise, more people are faced with the question of how their treatment might affect their ability to ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...